Real-World Effectiveness and Safety of Dotinurad in Chinese Patients with Gout: A Comparative Analysis
Guanqun Yi, Xuechan Huang, Yukai Huang, Zhixiang Huang, Shaoling Zheng, Zhengping Huang, Weiming Deng, Chun Zheng, Tianwang Li · 2026
Read Real-World Effectiveness and Safety of Dotinurad in Chinese Patients with Gout: A Comparative Analysis by Guanqun Yi, Xuechan Huang, Yukai Huang, Zhixiang Huang, Shaoling Zheng, Zhengping Huang, Weiming Deng, Chun Zheng, Tianwang Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13570847.txt.
Description
Yi and colleagues published a 2026 study on a newer gout drug used in China. Gout flares when uric acid builds up and crystals form in joints. Dotinurad lowers uric acid by blocking its reuptake in the kidneys. The team compared it with febuxostat, a standard option, in 70 patients.
After one month, 60 percent on dotinurad hit the main uric acid target. The febuxostat group reached that target in about 46 percent of cases. For the stricter target, dotinurad led by a wider margin still. Blood uric acid ended clearly lower in the dotinurad group at week four. Liver and kidney safety checks showed no added risk with dotinurad. Longer follow-up will show whether the early edge holds over time.
Catalog record
| CREATOR | Guanqun Yi, Xuechan Huang, Yukai Huang, Zhixiang Huang, Shaoling Zheng, Zhengping Huang, Weiming Deng, Chun Zheng, Tianwang Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |